Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

NEXT STORY
Aldo Esterhuizen, PhD, HCLD (ABB), Joins Ovation Fertility as Lab Director
PREV STORY
Immunoassay Market Worth $46.49 Billion by 2028 – Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update

author_avatar
NASDAQ Market News

ADMA Biologics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

RAMSEY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage ...

author_avatar
NASDAQ Market News

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

author_avatar
NASDAQ Market News